NCT03029247 - Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP) | Biotech Hunter

Enrollment

105

Participants

Timeline

Start Date

July 27, 2017

Primary Completion Date

July 9, 2020

Study Completion Date

July 9, 2020

Conditions

Anaemia

Interventions

DRUG

Daprodustat

Daprodustat will be available as oral tablets at unit dose strength of 1, 2, 4, 6, 8 and 10 mg.

DRUG

Epoetin alfa

Epoetin alfa will be administered according to local labelling and clinical practice guidelines to keep Hgb in the target range (10.0-11.0 g/dL)

Trial Locations (11)

GSK Investigational Site, Spartanburg

GSK Investigational Site, DeLand

GSK Investigational Site, Orlando

GSK Investigational Site, Hollywood

GSK Investigational Site, Miami

GSK Investigational Site, Coral Gables

GSK Investigational Site, Minneapolis

GSK Investigational Site, Chicago

GSK Investigational Site, San Antonio

GSK Investigational Site, Lakewood

GSK Investigational Site, La Mesa